Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Paul Brennan(University of Dundee), Jonathan Fallowfield(Centre for Inflammation Research), Rohit Loomba(University of California San Diego), Ahmed M. Elsharkawy(University Hospitals Birmingham NHS Foundation Trust), Timothy J. Kendall(Edinburgh Royal Infirmary), Derek A. Mann(Newcastle University)
Cited by 70
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k